Loading
A phase 2 trial of Tabelecleucel in brain and spinal cord tumours, sarcomas and uterine sarcoma, run by Pierre Fabre Medicament, active and no longer recruiting.
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases is a phase 2 interventional study registered as NCT04554914 by Pierre Fabre Medicament, with 190 participants enrolled, started 2021-07-14 and due to reach its primary completion in 2027-06. Interventions recorded: Tabelecleucel.
Shares Uterine sarcoma, Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Pierre Fabre and the tag pipeline.
Shares Pierre Fabre and the tag pipeline.
Shares Pierre Fabre and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Uterine sarcoma and the tag pipeline.
Shares Uterine sarcoma and the tag pipeline.